Burns Charest LLP
We are in a battle for the future of our democracy. The frontline is the courtroom. Sounds dramatic, doesn’t it? Maybe a little heavy-handed?
I write and speak like this because it matters. And I care.
At our founding, Thomas Jefferson said this: “I consider trial by jury as the only anchor ever yet imagined by man, by which government can be held to the principles of its constitution.”
Access to our courts is the bedrock of our democracy. But the truth is that the civil justice system in our country has been under assault for decades. Politicians have politicized our courts to a remarkable degree, undermining faith in the system. Powerful interest groups have convinced leaders and millions of ordinary citizens that lawsuits are abusive, even when they protect fundamental rights and the basic functioning of our economy. Wealthy corporations abuse the system every day, denying justice and barring the courthouse door to ordinary Americans.
So, what are we going to do? How do we fight back? It starts with your case.
Selecting a lawyer for your case is a very important decision. You want a lawyer who understands your concerns and will fight to achieve your goals. You want a lawyer who believes in our system and knows how to succeed in it. And, most importantly, you want a lawyer who is going to give you candid and meaningful advice. I am that lawyer.
I focus my practice on high-stakes antitrust litigation, along with other complex class action and commercial cases. I have tried and litigated numerous cases involving price fixing, monopolization, breach of contract, intellectual property, business torts, consumer protection statutes, and accounting malpractice.
I achieve results. In 2022, after five years of hard-fought litigation in Kansas City, Kansas, and on the eve of a trial that I was poised to lead, I inked a settlement with the remaining defendant in a nationwide antitrust and RICO class action against the manufacturer and marketer of the EpiPen. In total, the defendants paid $609 million to a class of people and businesses who had paid inflated prices for the lifesaving device. EpiPen was the first and only consumer and business case to take on corporations for headline-producing pharmaceutical price increases.
In 2012, I helped lead a trial team that took the first mortgage-backed-securities related case to trial. In a landmark and game-changing trial, we secured a $106 million judgment on behalf of our client and obtained key pre-trial determinations that had a domino effect in related cases.
I want to know more about your case and to see if there is a way I can help you. I look forward to talking with you.